He bashed MNTA for signing a partnership deal with Novartis saying it did not show value of technology as it was NOT (edited) a new partner and also bashing lack of cash upfront (other than for stock sell). He ignored fact that Novartis threw in two drugs of its own to get partnership. Contrast this to IDIX, whose hepatitis deals are with whom? Novartis. Which area is strongest at Novartis (hepatitis or generics - another edit here)? Generics. Which area is Novartis teaming with everyone? Hepatitis.
I happen to own both MNTA and IDIX (which is acting somewhat badly recently BTW) and am even breakeven on both. But I am calling this behavior out.
I am new here but have been an observer for a while. There is without question a not so subtle trend by the moderator to "bash" or ridicule stocks that he does not own.
I guess that is par for the course on such moderated boards.
Market Data 
Markets 
AI
